SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare informs about disclosure

15 Mar 2025 Evaluate
Shilpa Medicare has informed that United States Food and Drugs Administration (USFDA) has conducted an inspection at Unit-2 of Shilpa Pharma Lifesciences, located at Raichur from March 10-14, 2025. The inspection was closed with ZERO observations. This is second consecutive ZERO 483 inspection from USFDA at this site.

The above information is a part of company’s filings submitted to BSE.



Shilpa Medicare Share Price

410.70 -0.85 (-0.21%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×